Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2020 - 2025)

Tarsus Pharmaceuticals has reported Total Current Liabilities over the past 6 years, most recently at $135.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $135.7 million for Q4 2025, up 68.33% from a year ago — trailing twelve months through Dec 2025 was $135.7 million (up 68.33% YoY), and the annual figure for FY2025 was $135.7 million, up 68.33%.
  • Total Current Liabilities for Q4 2025 was $135.7 million at Tarsus Pharmaceuticals, up from $117.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TARS hit a ceiling of $135.7 million in Q4 2025 and a floor of $10.1 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $19.3 million (2022), compared with a mean of $42.7 million.
  • Biggest five-year swings in Total Current Liabilities: increased 5.11% in 2023 and later surged 249.28% in 2024.
  • Tarsus Pharmaceuticals' Total Current Liabilities stood at $11.5 million in 2021, then soared by 34.42% to $15.4 million in 2022, then soared by 139.39% to $36.9 million in 2023, then skyrocketed by 118.25% to $80.6 million in 2024, then surged by 68.33% to $135.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $135.7 million (Q4 2025), $117.0 million (Q3 2025), and $90.3 million (Q2 2025) per Business Quant data.